Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Intravenous tissue plasminogen activator for acute ischemic stroke in patients ≥80 years old:: The London, Canada experience
    Demaerschalk, B
    Merino, JG
    Silver, B
    Tamayo, A
    Wong, EH
    Devasenapathy, A
    O'Callaghan, C
    Kertesz, A
    Young, GB
    Spence, JD
    Hachinski, V
    STROKE, 2001, 32 (01) : 368 - 369
  • [12] Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients
    Berrouschot, J
    Röther, J
    Glahn, J
    Kucinski, T
    Fiehler, J
    Thomalla, G
    STROKE, 2005, 36 (11) : 2421 - 2425
  • [13] Intravenous Thrombolysis With Low-Dose Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
    Loh, Pei Kee
    Sharma, Vijay K.
    STROKE, 2010, 41 (03) : E164 - E164
  • [14] Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke
    Grond, M
    Rudolf, J
    Schmülling, S
    Stenzel, C
    Neveling, M
    Heiss, WD
    ARCHIVES OF NEUROLOGY, 1998, 55 (04) : 466 - 469
  • [15] Vascular Aphasia Outcome after Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Ischemic Stroke
    Jacquin, A.
    Virat-Brassaud, M. -E.
    Rouaud, O.
    Osseby, G. -V.
    Aboa-Eboule, C.
    Hervieu, M.
    Menassa, M.
    Ricolfi, F.
    Giroud, M.
    Bejot, Y.
    EUROPEAN NEUROLOGY, 2014, 71 (5-6) : 288 - 295
  • [16] Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban
    van Hooff, Robbert-Jan
    Nieboer, Koenraad
    De Smedt, Ann
    Yperzeele, Laetitia
    Jochmans, Kristin
    De Keyser, Jacques
    Brouns, Raf
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 122 : 133 - 134
  • [17] Intravenous Thrombolysis with Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke in Patients with Metabolic Syndrome
    Sobolewski, Piotr
    Brola, Waldemar
    Szczuchniak, Wiktor
    Fudala, Magorzata
    Kozera, Grzegorz
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (08): : 1787 - 1792
  • [18] Tissue plasminogen activator (tPA) for ischemic stroke in patients aged ≥ 80 years
    Zhou, C.
    Zhu, L.
    Wu, J.
    Fang, S.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 128 (03): : e17 - e18
  • [19] Update on Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
    Fugate, Jennifer E.
    Rabinstein, Alejandro A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (07) : 960 - 972
  • [20] The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke
    Kahn, JH
    Viereck, J
    Kase, C
    Jeerakathil, T
    Romero, R
    Mehta, SD
    Kociol, R
    Babikian, V
    JOURNAL OF EMERGENCY MEDICINE, 2005, 29 (03): : 273 - 277